You just read:

Hetero Launches Biosimilar 'Bevacizumab' for the Treatment of Metastatic Colorectal Cancer (mCRC) Under the Brand Name 'CizumabTM'

News provided by

Hetero

Jun 27, 2016, 10:03 ET